Outcome of transplantation performed outside the regular working hours: a systematic review and meta-analysis of the literature
Transplant procedures are frequently performed outside the regular working hours (after hours). In general surgery, several studies observed worse outcomes for operations performed after hours. The predetermined hypothesis was that patients undergoing transplantation during after hours might suffer from an excess in post-operative mortality and morbidity when compared to patients undergoing transplantations during the regular working hours. A systematic review of the PubMed database identified 11,993 records, of which eleven cohort studies including a total of 287,741 patients investigated the association between the start...
Source: Transplantation Reviews - May 8, 2018 Category: Transplant Surgery Authors: Jore Hendrikx, Dirk Van Raemdonck, Jacques Pirenne, Steffen Fieuws, Steffen Rex Tags: Review article Source Type: research
The clinical impact of donor-specific antibodies in heart transplantation
Donor-specific antibodies (DSA) are integral to the development of antibody-mediated rejection (AMR). Chronic AMR is associated with high mortality and an increased risk for cardiac allograft vasculopathy (CAV). Anti-donor HLA antibodies are present in 3 –11% of patients at the time of heart transplantation (HTx), with de novo DSA (predominantly anti-HLA class II) developing post-transplant in 10–30% of patients. DSA are associated with lower graft and patient survival after HTx, with one study suggesting a three-fold increase in mortality in pa tients who develop de novo DSA. (Source: Transplantation Reviews)
Source: Transplantation Reviews - May 8, 2018 Category: Transplant Surgery Authors: Markus J. Barten, Uwe Schulz, Andres Beiras-Fernandez, Michael Berchtold-Herz, Udo Boeken, Jens Garbade, Stephan Hirt, Manfred Richter, Arjang Ruhpawar, Tim Sandhaus, Jan Dieter Schmitto, Felix Sch önrath, Rene Schramm, Martin Schweiger, Markus Wilhelm, Tags: Review article Source Type: research
A Review of the Use of Direct Oral Anticoagulant Use in Orthotopic Heart Transplantation Recipients
Over 60 years ago, the vitamin K antagonist (VKA) warfarin was approved and remained the only oral anticoagulation agent until recently [1]. Currently, within North America and Europe there are four DOACs available. Dabigatran, first approved in Europe and Canada in 2008, then in the United States of America in 2010, followed by rivaroxaban, apixaban, and most recently edoxaban. The introduction of direct oral anticoagulants (DOACs) has been a major advancement and these agents are the preferred to VKAs for many indications [2 –5], including stroke prevention in nonvalvular atrial fibrillation (NVAF), acute treatment and...
Source: Transplantation Reviews - April 16, 2018 Category: Transplant Surgery Authors: Rosaleen Boswell, Glen J. Pearson Tags: Review article Source Type: research
Challenges of immunosuppressive and antitrypanosomal drug therapy after heart transplantation in patients with chronic Chagas disease: A systematic review of clinical recommendations
Although contraindicated for decades, heart transplantation (HT) has finally become a feasible therapeutic option for the treatment of Chagasic patients with end-stage heart failure. Part of the success in achieving acceptable survival rates after HT is due to the enhancement of the pharmacological management of allograft rejection and reactivation of Trypanosoma cruzi infection. (Source: Transplantation Reviews)
Source: Transplantation Reviews - April 16, 2018 Category: Transplant Surgery Authors: Silas Santana Nogueira, Amanda Aparecida Felizardo, Ivo Santana Caldas, Reggiani Vilela Gon çalves, Rômulo Dias Novaes Tags: Review article Source Type: research
A Review of the Use of Direct Oral Anticoagulant Use in Orthotopic Heart Transplantation Recipients
Over 60 years ago, the vitamin K antagonist (VKA) warfarin was approved and remained the only oral anticoagulation agent until recently [1]. Currently, within North America and Europe there are four DOACs available. Dabigatran, first approved in Europe and Canada in 2008, then in the United States of America in 2010, followed by rivaroxaban, apixaban, and most recently edoxaban. The introduction of direct oral anticoagulants (DOACs) has been a major advancement and these agents are the preferred to VKAs for many indications [2 –5], including stroke prevention in nonvalvular atrial fibrillation (NVAF), acute treatment and...
Source: Transplantation Reviews - April 16, 2018 Category: Transplant Surgery Authors: Rosaleen Boswell, Glen J. Pearson Tags: Review article Source Type: research
Challenges of immunosuppressive and antitrypanosomal drug therapy after heart transplantation in patients with chronic Chagas disease: A systematic review of clinical recommendations
Although contraindicated for decades, heart transplantation (HT) has finally become a feasible therapeutic option for the treatment of Chagasic patients with end-stage heart failure. Part of the success in achieving acceptable survival rates after HT is due to the enhancement of the pharmacological management of allograft rejection and reactivation of Trypanosoma cruzi infection. (Source: Transplantation Reviews)
Source: Transplantation Reviews - April 16, 2018 Category: Transplant Surgery Authors: Silas Santana Nogueira, Amanda Aparecida Felizardo, Ivo Santana Caldas, Reggiani Vilela Gon çalves, Rômulo Dias Novaes Tags: Review article Source Type: research
Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression
Changes in recipient and donor characteristics are redefining the role of induction in liver transplant recipients. Older recipients are more common, with greater concomitant comorbidity. Moderate or severe renal dysfunction is now estimated to affect 40% of liver transplant recipients. Donors are also becoming older, and other factors such as more frequent non-alcoholic fatty liver disease (NAFLD) compromise the quality of some grafts. Rejection rates are now relatively low (~10%) but some patients have a markedly increased risk such as younger recipients and those undergoing re-transplantation. (Source: Transplantation Reviews)
Source: Transplantation Reviews - April 13, 2018 Category: Transplant Surgery Authors: Umberto Cillo, Wolf O. Bechstein, Gabriela Berlakovich, Philipp Dutkowski, Frank Lehner, Silvio Nadalin, Faouzi Saliba, Hans J. Schlitt, Johann Pratschke Tags: Review article Source Type: research
Ex situ liver perfusion: Organ preservation into the future
In recent years, remarkable progress has occurred in the development of technologies to support ex situ liver perfusion. Building upon extensive preclinical studies in large animal models, pilot and randomized clinical trials have been initiated, and preliminary outcomes suggest more optimal protection of both standard and extended criteria liver grafts. There currently exists an incredible opportunity and need to further refine this technology, determine appropriate viability measures to predict usable liver grafts, and to explore potent protective additive strategies to further optimize the quality of extended criteria o...
Source: Transplantation Reviews - April 4, 2018 Category: Transplant Surgery Authors: Mariusz Bral, Boris Gala-Lopez, David L. Bigam, Darren H. Freed, A.M. James Shapiro Tags: Review article Source Type: research
Ex Situ Liver Perfusion: Organ Preservation Into the Future
In recent years, remarkable progress has occurred in the development of technologies to support ex situ liver perfusion. Building upon extensive preclinical studies in large animal models, pilot and randomized clinical trials have been initiated, and preliminary outcomes suggest more optimal protection of both standard and extended criteria liver grafts. There currently exists an incredible opportunity and need to further refine this technology, determine appropriate viability measures to predict usable liver grafts, and to explore potent protective additive strategies to further optimize the quality of extended criteria o...
Source: Transplantation Reviews - April 4, 2018 Category: Transplant Surgery Authors: Mariusz Bral, Boris Gala-Lopez, David L. Bigam, Darren H. Freed, A.M. James Shapiro Tags: Review article Source Type: research
ditorial Board
(Source: Transplantation Reviews)
Source: Transplantation Reviews - April 1, 2018 Category: Transplant Surgery Source Type: research
Instructions for Authors
(Source: Transplantation Reviews)
Source: Transplantation Reviews - April 1, 2018 Category: Transplant Surgery Source Type: research
Previous issue
(Source: Transplantation Reviews)
Source: Transplantation Reviews - April 1, 2018 Category: Transplant Surgery Source Type: research
Review: Management of patients with kidney allograft failure
Late allograft loss in kidney transplant recipients remains a common problem and is associated with high mortality and morbidity. The management of patients with a failed kidney allograft includes a few major dilemmas: when to start dialysis, what is the optimal management regarding immunosuppression, and should an allograft nephrectomy be performed. In suitable candidates for a repeated transplantation there are additional matters to take in consideration. In this review we will discuss these dilemmas by providing an overview of current evidence and gaps in our knowledge. (Source: Transplantation Reviews)
Source: Transplantation Reviews - March 29, 2018 Category: Transplant Surgery Authors: Kim L.W. Bunthof, Marc Hazzan, Luuk B. Hilbrands Tags: Review article Source Type: research
